Glaxo Blood Cancer Treatment Wins Backing From FDA Committee
5 years ago 1 min read
GlaxoSmithKline Plc took a step forward in its bid for U.S. approval of a novel blood cancer drug, after a panel advising the Food and Drug Administration voted in favor of its use.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push